- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01325220
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (Harbor-C)
July 30, 2013 updated by: Seaside Therapeutics, Inc.
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
There will be four study periods: Screening (up to 14 days in length), the Treatment Period (8 weeks), the Withdrawal Period (22 days), and Follow-up Period (up to 31 days).
Subjects will be randomized to receive either STX209 (5 mg twice daily [BID], 10 mg BID or 10 mg three times daily [TID]) or placebo.
Efficacy,safety and tolerability assessments will be performed periodically
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
172
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Southwest Autism Research & Resource Center
-
-
California
-
Long Beach, California, United States, 90806
- Miller Children's Hospital
-
Sacramento, California, United States, 95817
- University of California-Davis, M.I.N.D. Institute
-
San Diego, California, United States, 92108
- Psychiatric Centers at San Diego
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Denver, Children's Hospital
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami, Mailman Center for Child Development
-
Orange City, Florida, United States, 32763
- Lake Mary Pediatrics
-
-
Georgia
-
Decatur, Georgia, United States, 30033
- Emory University School of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- Kansas University Clinical Research Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Kennedy Krieger Institute
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- University of Massachusetts
-
-
Michigan
-
Detriot, Michigan, United States, 48201
- Children's Hospital of Michigan
-
-
Missouri
-
Columbia, Missouri, United States, 65211
- University of Missouri, Thompson Research Center for Autism & Neurodevelopmental Disorders
-
-
New York
-
New York, New York, United States, 10029
- Seaver Autism Center, Mount Sinai Medical Center
-
Staten Island, New York, United States, 10314
- New York State Institute for Basic Research in Developmental Disabilities
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Clinical Research Unit
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Akron Children's Hospital
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73117
- University of Oklahoma, Physician's Child Study Center
-
-
Pennsylvania
-
Media, Pennsylvania, United States, 19063
- Suburban Research Associates/Elwyn Genetics
-
-
South Carolina
-
Greenwood, South Carolina, United States, 29646
- Greenwood Genetics Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Vanderbilt Kennedy Center
-
-
Texas
-
Dallas, Texas, United States, 75235
- Childrens Medical Center Dallas
-
Houston, Texas, United States, 77030
- Texas Children's Hospital
-
Houston, Texas, United States, 77090
- Red Oaks Psychiatry Associates, P.A.
-
San Antonio, Texas, United States, 78258
- Road Runner Research
-
-
Washington
-
Seattle, Washington, United States, 98101
- Seattle Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 11 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Molecular documentation of the full FMR1 mutation
- Current pharmacological treatment regimen has been stable for at least 4 weeks prior to Screening.
- Subjects with a history of seizure disorder must currently be receiving treatment with antiepileptics and must have been seizure free for 6 months, or must be seizure free for 3 years if not currently receiving antiepileptics.
- If the subject is already receiving stable non-pharmacologic educational, behavioral, and/or dietary interventions, participation in these programs must have been continuous during the 2 months prior to Screening
Exclusion Criteria:
- Subjects with any condition, including alcohol and drug abuse, which might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being.
- Subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study.
- Subjects who have taken another investigational drug within the last 30 days.
- Subjects who are not able to take oral medications
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
tid
|
Active Comparator: STX209 5 mg BID
|
5 mg bid
Other Names:
10 mg bid
Other Names:
10 mg tid
Other Names:
|
Active Comparator: STX209 10 mg BID
|
5 mg bid
Other Names:
10 mg bid
Other Names:
10 mg tid
Other Names:
|
Active Comparator: STX209 10 mg TID
|
5 mg bid
Other Names:
10 mg bid
Other Names:
10 mg tid
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Aberrant Behavior Checklist-Lethargy Social Withdrawal subscale
Time Frame: at 8 weeks of treatment
|
This is a single subscale of the aberrant behavior checklist entitiled Lethargy Social Withdrawal
|
at 8 weeks of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
March 28, 2011
First Submitted That Met QC Criteria
March 28, 2011
First Posted (Estimate)
March 29, 2011
Study Record Updates
Last Update Posted (Estimate)
July 31, 2013
Last Update Submitted That Met QC Criteria
July 30, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Chromosome Disorders
- Sex Chromosome Disorders
- Syndrome
- Fragile X Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- GABA Agents
- Neuromuscular Agents
- Muscle Relaxants, Central
- GABA Agonists
- GABA-B Receptor Agonists
- Baclofen
Other Study ID Numbers
- 209FX302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fragile X Syndrome
-
University of California, DavisNational Institute of Mental Health (NIMH)CompletedFragile X PremutationUnited States
-
University of California, DavisNational Institute on Aging (NIA); Forest LaboratoriesCompletedFragile X-Associated Tremor/Ataxia Syndrome | Fragile X Premutation CarriersUnited States
-
Ovid Therapeutics Inc.CompletedFragile X Syndrome (FXS)United States
-
Guido A. Davidzon, MD, SMWithdrawn
-
Marinus PharmaceuticalsUniversity of California, Davis; U.S. Army Medical Research and Development...Completed
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedFragile X Syndrome (FXS)United States
-
Novartis PharmaceuticalsTerminated
-
Sheba Medical CenterElMindA LtdRecruitingFragile X Associated Tremor-ataxia Syndrome | FXTASIsrael
-
University of California, DavisUniversity of Alberta; St. Justine's HospitalRecruitingNeurobehavioral Manifestations | Genetic Diseases, X-Linked | Intellectual Disability | Fragile X Syndrome | Sex Chromosome Disorders | Fragile X Mental Retardation Syndrome | Trinucleotide Repeat Expansion | Fra(X) Syndrome | FXS | Mental Retardation, X LinkedUnited States, Canada
-
University of AlbertaSt. Justine's HospitalRecruitingNeurobehavioral Manifestations | Genetic Diseases, X-Linked | Mental Retardation, X-Linked | Intellectual Disability | Fragile X Syndrome | Sex Chromosome Disorders | Fragile X Mental Retardation Syndrome | Trinucleotide Repeat Expansion | Fra(X) Syndrome | FXSCanada
Clinical Trials on arbaclofen
-
RVL Pharmaceuticals, Inc.Osmotica Pharmaceutical US LLCWithdrawnMultiple Sclerosis | SpermUnited States
-
RVL Pharmaceuticals, Inc.Osmotica Pharmaceutical US LLCCompletedMultiple Sclerosis | SpasticityUnited States, Russian Federation, Ukraine
-
Timothy RobertsSimons Foundation; Clinical Research Associates, LLCCompleted
-
Evdokia AnagnostouMcMaster University; Unity Health Toronto; University of Toronto; University of... and other collaboratorsActive, not recruitingAutism Spectrum DisorderCanada
-
Seaside Therapeutics, Inc.TerminatedAutism Spectrum DisordersUnited States
-
Seaside Therapeutics, Inc.TerminatedFragile X SyndromeUnited States
-
Seaside Therapeutics, Inc.CompletedOpen-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum DisordersAutism Spectrum DisordersUnited States
-
Seaside Therapeutics, Inc.CompletedFragile X SyndromeUnited States
-
RVL Pharmaceuticals, Inc.Osmotica Pharmaceutical US LLCCompletedMultiple Sclerosis | Spasticity, MuscleSerbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
-
Seaside Therapeutics, Inc.CompletedFragile X SyndromeUnited States